Metastatic castration-resistant prostate cancer. research hub

SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

This study looks at a new drug, ODM-208, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It checks if the drug is safe, what dose works best, and how it moves through the body.

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

This study looks at a new drug, 177Lu-TLX591, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It compares this new drug combined with standard treatments to standard treatments alone.

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

This study is looking at new ways to treat advanced prostate cancer that has spread and medicines like hormone therapy no longer work. Researchers are testing the drug pembrolizumab, sometimes with other treatments, to see if it's safe and effective, aiming to find better options for patients.

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread and is no longer responding to hormone treatment. We want to see if it works better and is safer than standard treatments chosen by doctors.

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

This study is testing a new radioactive drug called Actinium (225Ac) rhPSMA-10.1 for men with advanced prostate cancer that has spread. It aims to find a safe dose and see how well it works, especially for those who've already had a similar treatment.

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

This study is testing a new drug, AZD2265, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if AZD2265 works better than current treatments at slowing down cancer growth and helping men live longer.

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

This study looks at a new drug, AAA617, for men with advanced prostate cancer that has spread. We want to find the safest dose, check for side effects, and see how well it works when given for a longer time.

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

This study is testing a new treatment, BAY3546828, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to find a safe and effective dose, understand how it works in the body, and see if it can shrink tumours.

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study is looking into a new drug, PF-06821497, combined with an existing drug, enzalutamide, for men with advanced prostate cancer. It wants to see if this combination works better than enzalutamide alone for those who haven't had certain other treatments.

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

This study is testing a new treatment for advanced prostate cancer that has spread and isn't responding to usual hormone therapy. It's called 177Lu-rhPSMA-10.1 and uses radiation to target cancer cells. We want to see how safe and effective it is.

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

This study is looking at a new treatment, Xaluritamig, combined with Abiraterone, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It compares this combination to standard treatments to see if it helps men live longer.

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

This study looks at a new injection, ASP5541, for advanced prostate cancer that has spread. It compares ASP5541 to a standard tablet treatment, abiraterone acetate, to see how safe and effective it is.

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

This study looks at a new treatment, [Lu-177]-PNT2002, for advanced prostate cancer that has spread and isn't responding to standard hormone therapy. It compares this new treatment with existing hormone therapies to see if it can slow down cancer growth.

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

This study is looking at a new prostate cancer drug, JNJ-56021927, alongside existing treatments like abiraterone acetate and prednisone. Researchers want to see if these drugs work well together, check for side effects, and find the best doses for future studies in men with advanced prostate cancer.

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

This study looks at a new combination treatment for advanced prostate cancer that has spread. It compares olaparib plus abiraterone with abiraterone alone to see if the new combination works better and is safe for men who haven't had previous strong treatments.

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer

A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

This study is testing a new drug, DS9051b, for people with advanced adrenal gland cancer or prostate cancer that has spread. Researchers want to see if it's safe, how much to give, and if it shows early signs of working.